The LAM-PCR protocol was used to determine the integration site profile of retroviral-based vectors within the genome of CD34+ hematopoietic stem cells of two patients with Wiskott-Aldrich syndrome (WAS), who participated in a phase I gene therapy clinical trial [76–78]. This evidence concerns the gene CD34 and Wiskott-Aldrich syndrome.